Teriflunomide, a potential novel cause of chronic active colitis.Histopathology. 2020 Apr 23 [Online ahead of print]H
Teriflunomide is a novel pyrimidine synthesis inhibitor which limits immune response by selectively blocking dihydroorotate dehydrogenase, required by rapidly dividing B and T lymphocytes . It is indicated as a first-line treatment for relapsing-remitting multiple sclerosis (RRMS). The most common adverse reactions reported in patients receiving either 7 or 14 mg daily include headache (18% and 16%), elevated alanine aminotransferase (13% and 15%), diarrhea (13% and 14%), alopecia (10% and 13%), and nausea (8% and 11%), respectively .